Abridge, a healthcare AI company founded in 2018, has emerged as a major player in clinical automation, projecting support for over 80 million patient-clinician conversations across 250 U.S. health systems this year. The company's approach differs from typical AI startups by focusing on unglamorous foundational work: building trust in sensitive healthcare workflows through careful integration with electronic health record systems, clinician verification processes, and the complex realities of how health systems actually purchase and deploy technology. The company's initial wedge—converting clinical conversations into automated documentation notes—has evolved into a broader clinical intelligence platform. By saving clinicians 10 to 20 hours per week on administrative work, Abridge has demonstrated concrete value that translates across billing, prior authorization, quality assurance, and patient follow-up workflows. The company's latest $300 million funding round at a $5.3 billion valuation, announced in June 2025, underscores investor confidence in its ability to expand beyond documentation into real-time clinical decision support and automated prior authorization processes. Abridge's success reflects a broader shift in enterprise AI deployment: the company emphasizes context-aware systems built for specific industries rather than general-purpose applications. With support for 28 languages and 50+ medical specialties, the platform demonstrates how specialized evaluation frameworks and clinician-scientist teams can solve some of AI's hardest problems while maintaining safety standards critical to healthcare.